ContributorsPublishersAdvertisers

#Indolent Lymphoma

targetedonc.com

Idelalisib for Relapsed FL and SLL Voluntarily Withdrawn from US Market

Without confirmed clinical benefit in follicular lymphoma and small lymphocytic leukemia, idelalisib's indications for these malignancies were withdrawn from the United States market. The developer of idelalisib (Zydelig), Gilead, has announced the withdrawal of 2 indications for the agent from the United States (US), according to a press release. Idealisib...
MEDICAL & BIOTECH
Picture for Idelalisib for Relapsed FL and SLL Voluntarily Withdrawn from US Market
gilead.com

Gilead Statement on Zydelig® U.S. Indication for Follicular Lymphoma and Small Lymphocytic Leukemia

– In 2014, Zydelig® (idelalisib) received accelerated approval from the U.S. Food and Drug Administration (FDA) to treat relapsed follicular B-cell non-Hodgkin lymphoma (FL) and relapsed small lymphocytic leukemia (SLL). Approval was based on a Phase 2 study in indolent non-Hodgkin lymphoma showing that 54% of those with FL and 58% of those with SLL had an objective response as assessed by an Independent Review Committee.
MEDICAL & BIOTECH
onclive.com

Dr. Goy on the Utility of Axi-Cel and Brexu-Cel in Relapsed/Refractory Non-Hodgkin Lymphoma

Andre H. Goy, MD, discusses the clinical data reported with axicabtagene ciloleucel in patients with relapsed or refractory indolent non-Hodgkin lymphoma and real-world findings with brexucabtagene autoleucel in mantle cell lymphoma. Andre H. Goy, MD, physician in chief, Hackensack Meridian Health Oncology Care Transformation Service; chairman & chief physician officer,...
CANCER
TRENDING TOPICS
MedicineNet.com

What Were Your First Signs of Lymphoma?

Early lymphoma symptoms can be minor or mimic common illnesses. Lymphoma typically manifests as a painless lump or mass in the lymph nodes, usually in the neck, armpit, or groin. A physician should examine any painless, firm lumps or masses on your neck, armpit, or groin. Here are 11 early...
CANCER
insideprecisionmedicine.com

CAR T-Cell Therapy for High-Risk Lymphoma Makes Case as Standard-of-Care Treatment

Data from three separate clinical studies, released at the American Society Hematology (ASH) conference in December by researchers from the MD Anderson Cancer Center, showed enhanced response in patients with high-risk lymphoma when treated with axicabtagene ciloleucel (axi-cel) chimeric antigen receptor (CAR) T-cell therapy. Axi-cel is an autologous anti-CD19 CAR...
CANCER
onclive.com

Dr. Leslie on Axi-Cel Vs SOC in Relapsed/Refractory Large B-Cell Lymphoma

Lori A. Leslie, MD, discusses results from the primary analysis of the phase 3 ZUMA‑7 trial, which evaluated axicabtagene ciloleucel vs standard‑of‑care therapy in patients with relapsed or refractory large B-cell lymphoma. Lori A. Leslie, MD, assistant professor, Hackensack Meridian School of Medicine, director, Indolent Lymphoma and...
HACKENSACK, NJ
tekdeeps.com

Global market new drug development caught in lymphoma

[헬스코리아뉴스 / 박민주] The new drug that major multinational pharmaceutical companies are most painstakingly developing is a lymphoma treatment (anti-cancer drug), it has been found. This is the part where you can read the trend of new drug development in the global market.
MEDICAL & BIOTECH
onclive.com

Zandelisib Elicits High Response Rates in Relapsed/Refractory Follicular Lymphoma

Zandelisib demonstrated significant activity and an encouraging preliminary safety profile in patients with relapsed/refractory follicular lymphoma who have received at least 2 prior systemic therapies. Zandelisib demonstrated significant activity and an encouraging preliminary safety profile in patients with relapsed/refractory follicular lymphoma who have received at least 2 prior systemic therapies,...
CANCER
patientpower.info

ASH 2021: Updates to the Standard of Care for DLBCL

For twenty years R-CHOP has been the standard of care for the treatment of diffuse large B-cell lymphoma (DLBCL). At the 2021 American Society of Hematology (ASH) conference, new data suggest that the standard might need to be adjusted. Brian Hill, MD, PhD, Director of the Lymphoid Malignancies Program at the Cleveland Clinic, explains updates in the treatment of DLBCL including CAR T-cell therapy and the future of autologous stem cell transplant.
CANCER
pharmacytimes.com

Marginal Zone Lymphoma: Subtypes, Treatments, the Role of the Pharmacist

Although marginal zone lymphoma is relatively rare, it contains a broad spectrum of conditions under it that require an individualized treatment selection process. Marginal zone lymphoma (MZL)—a low-grade, B-cell, non-Hodgkin lymphoma—is relatively rare, explained a panel of experts during an Insights series video discussion for Pharmacy Times.® The disease arises from a marginal zone of the lymph nodes, spleen, or mucosa-associated lymphoid tissue (MALT), and accounts for around 10% of non-Hodgkin lymphoma cases.
DISEASES & TREATMENTS
YOU MAY ALSO LIKE